Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Novan, Inc.NOVN · Entity 111882 | Director | June 04, 2018 | June 07, 2018 |
| Poseida Therapeutics, Inc.PSTX · Entity 84243 | Director · 10% owner | July 14, 2020 | July 15, 2020 |
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director | June 12, 2025 | June 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Novan, Inc.
Report date June 04, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.08 · Expires 2028-06-03 | Direct | 20,000 |
Reported balance
After 2018-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-04 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests in four equal quarterly installments, with the first installment vesting on September 4, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal quarterly installments, with the first installment vesting on September 4, 2018.
Poseida Therapeutics, Inc.
Report date July 14, 2020 · Filed July 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 9,188,125 |
Last balance in matching sequence
After 2020-07-14 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2020-07-14 · Conversion · Acquired 7,013,918 · Balance 7,013,918 F1: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 2 · 2020-07-14 · Conversion · Acquired 1,168,985 · Balance 8,182,903 F1: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 3 · 2020-07-14 · Conversion · Acquired 690,124 · Balance 8,873,027 F1: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 4 · 2020-07-14 · Conversion · Acquired 315,098 · Balance 9,188,125 F1: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2020-07-14 transaction · row 5
1 source rowRow 5 · 2020-07-14 · Purchase · Acquired 10,000 · Balance 10,000 |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-07-14 · Conversion · Disposed 8,746,356 · Balance 0 F1: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-14 · Conversion · Disposed 1,457,725 · Balance 0 F1: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-14 · Conversion · Disposed 860,585 · Balance 0 F1: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-07-14 · Conversion · Disposed 392,927 · Balance 0 F1: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
TriSalus Life Sciences, Inc.
Report date June 12, 2025 · Filed June 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2035-06-11 | Direct | 554,681 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 15,000 · Balance 554,681 F1: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Radius Health, Inc.
Report date August 15, 2022 · Filed August 15, 2022
Section 16 reporting ended · disclosed 2022-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-15 transaction · row 1
1 source rowRow 1 · 2022-08-15 · Other · Disposed 5,500 · Balance 0 F1: Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2032-01-14 | Direct | 0 |
Reported balance
After 2022-08-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share.
F2: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 27, 2025 16:18 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001826667-25-000083 · wk-form4_1751055493.xml · derivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 554,681 Underlying: Common Stock · 15,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 19, 2025 Filed May 21, 2025 17:28 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 44,884 | $5.18 | $232,499.12 |
DisclosureSEC source: 0001826667-25-000055 · wk-form4_1747862929.xml · nonDerivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,989 F1 · shares: The granted RSUs vest immediately. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 17:54 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 15,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004691 · form4-02192025_100215.xml · nonDerivative · entry 1 Murphy Sean · CIK 0001685042 · Director · Chief Manuf, Strategy&Bus Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,105 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 12.5% of the shares subject to the RSU Award shall vest on the grant date of February 18, 2025; 25% of the shares subject to the RSU Award shall vest on each of May 15, 2025, August 15, 2025, and November 14, 2025; and the remaining shares subject to the RSU Award will vest on February 13, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 18:13 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 15,000 | $5.17 | $77,550.00 |
DisclosureSEC source: 0001415889-25-002291 · form4-01292025_110106.xml · nonDerivative · entry 3 Murphy Sean · CIK 0001685042 · Director · Chief Manuf, Strategy&Bus Dev. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sean E Murphy TTEE U/A 2/4/2004 Disclosed balance after: 197,732 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.94 to $5.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 18:13 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001415889-25-002291 · form4-01292025_110106.xml · derivative · entry 5 Murphy Sean · CIK 0001685042 · Director · Chief Manuf, Strategy&Bus Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-01-26 F5 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of January 1, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 18:13 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 15,000 | $5.31 | $79,650.00 |
DisclosureSEC source: 0001415889-25-002291 · form4-01292025_110106.xml · nonDerivative · entry 2 Murphy Sean · CIK 0001685042 · Director · Chief Manuf, Strategy&Bus Dev. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sean E Murphy TTEE U/A 2/4/2004 Disclosed balance after: 182,732 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.09 to $5.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 18:13 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002291 · form4-01292025_110106.xml · nonDerivative · entry 1 Murphy Sean · CIK 0001685042 · Director · Chief Manuf, Strategy&Bus Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,288 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on January 1, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 18:17 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001415889-24-003806 · form4-02142024_110255.xml · derivative · entry 4 Murphy Sean · CIK 0001685042 · Director · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2034-02-11 F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 12, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 18:17 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 34,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003806 · form4-02142024_110255.xml · nonDerivative · entry 1 Murphy Sean · CIK 0001685042 · Director · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,788 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 12, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 17:46 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001415889-24-001820 · form4-01252024_100149.xml · derivative · entry 1 Murphy Sean · CIK 0001685042 · Director · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of January 24, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 19:21 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045730 · doc4.xml · derivative · entry 1 Murphy Sean · CIK 0001685042 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-08-10 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 16:14 UTC | Radius Health, Inc. RDUS · Entity 124173 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | $3.60 Strike: $6.40 | $36,000.00 |
DisclosureSEC source: 0000899243-22-028633 · doc4.xml · derivative · entry 2 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-01-14 F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 16:14 UTC | Radius Health, Inc. RDUS · Entity 124173 | OtherCommon Stock | 5,500 | $10.00 | $55,000.00 |
DisclosureSEC source: 0000899243-22-028633 · doc4.xml · nonDerivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. F1 · price: Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. Read SEC document |
| January 14, 2022 Filed Jan 25, 2022 16:30 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-22-004786 · doc4.xml · derivative · entry 2 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-14 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date. Read SEC document |
| January 14, 2022 Filed Jan 25, 2022 16:30 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004786 · doc4.xml · nonDerivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 17:58 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.60 | $0.00 |
DisclosureSEC source: 0001209191-21-013347 · doc4.xml · derivative · entry 2 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-02-22 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 17:58 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-013347 · doc4.xml · nonDerivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 17:13 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005129 · doc4.xml · derivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-21 F1 · derivative.exercise_date: This option shall vest in full on the first anniversary of the grant date or upon an earlier Change of Control (as defined in the registrant's 2018 Stock Option and Incentive Plan). Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 16:33 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $12.61 | $0.00 |
DisclosureSEC source: 0001209191-20-046375 · doc4.xml · derivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-08-10 F1 · derivative.exercise_date: This option shall vest in substantially equal installments on each of the first four anniversaries of August 10, 2020. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionSeries C Preferred Stock · Derivative | 392,927 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042500 · doc4.xml · derivative · entry 9 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 315,098 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionSeries B Preferred Stock · Derivative | 860,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042500 · doc4.xml · derivative · entry 8 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 690,124 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionSeries A-1 Preferred Stock · Derivative | 1,457,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042500 · doc4.xml · derivative · entry 7 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,168,985 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionSeries A Preferred Stock · Derivative | 8,746,356 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042500 · doc4.xml · derivative · entry 6 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 7,013,918 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | PurchaseCommon Stock | 10,000 | $16.00 | $160,000.00 |
DisclosureSEC source: 0001209191-20-042500 · doc4.xml · nonDerivative · entry 5 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionCommon Stock | 315,098 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042500 · doc4.xml · nonDerivative · entry 4 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,188,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionCommon Stock | 690,124 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042500 · doc4.xml · nonDerivative · entry 3 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,873,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionCommon Stock | 1,168,985 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042500 · doc4.xml · nonDerivative · entry 2 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,182,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionCommon Stock | 7,013,918 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042500 · doc4.xml · nonDerivative · entry 1 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,013,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares of common stock issuable upon conversion of preferred stock held by Malin Holdings, a wholly owned subsidiary of Malin Corporation plc ("Malin"), and may be deemed to be beneficially owned by Malin. Malin may be deemed to share voting and investment power over securities held by Malin Holdings. Mr. Murphy currently serves as a member of the leadership team at Malin. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 19:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042312 · doc4.xml · derivative · entry 1 Murphy Sean · CIK 0001685042 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-07-08 F1 · derivative.exercise_date: The stock option will vest and become exercisable in 12 equal monthly installments from the date of grant. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 20:53 UTC | Novan, Inc. NOVN · Entity 111882 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-18-036553 · doc4.xml · derivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-03 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on September 4, 2018. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 18:03 UTC | Novan, Inc. NOVN · Entity 111882 | GrantStock Option (right to buy) · Derivative | 34,014 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001209191-17-038402 · doc4.xml · derivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,014 Underlying: Common Stock · 34,014 shares Expires 2027-06-04 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on September 5, 2017. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 16:46 UTC | Novan, Inc. NOVN · Entity 111882 | GrantStock Option · Derivative | 14,484 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029753 · doc4.xml · derivative · entry 1 Murphy Sean · CIK 0001685042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,484 Underlying: Common Stock · 14,484 shares Expires 2026-09-19 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on December 20, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.